NEWS

Aug 18, 2023

Amber Ophthalmics announces first patient enrolled in AMB-01-006 (NEXPEDE-1)

NEXPEDE-1 is a Phase 2/3 clinical trial evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects

Apr 22, 2023

2023 ARVO Annual Meeting

Amber Ophthalmics to present Phase 2 study results for NEXAGON in subjects with PCED at ARVO Annual Meeting

Jan 9, 2023

Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating NEXAGON® For the Treatment of Persistent Corneal Epithelial Defect (PCED)

• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone
• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle
• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023

Dec 9, 2022

J.P. Morgan Health Care Conference 2023

Amber Ophthalmics to attend the J.P. Morgan Health Care Conference in San Francisco, CA